scispace - formally typeset
F

Fu-Sheng Wang

Researcher at Chinese PLA General Hospital

Publications -  372
Citations -  29480

Fu-Sheng Wang is an academic researcher from Chinese PLA General Hospital. The author has contributed to research in topics: Medicine & Immune system. The author has an hindex of 61, co-authored 297 publications receiving 21496 citations. Previous affiliations of Fu-Sheng Wang include Chinese Center for Disease Control and Prevention & Fourth Military Medical University.

Papers
More filters
Journal ArticleDOI

High circulating CD39 + regulatory T cells predict poor survival for sepsis patients

Hui-Huang Huang, +14 more
- 01 Jan 2015 - 
TL;DR: It is suggested that CD39(+) Treg levels could be used as a biomarker to predict the outcome of sepsis patients, after it was found that a highCD39(-) Tregs percentage and MFI on overall survival was associated with a poor prognosis for sepsi patients.
Journal ArticleDOI

Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial

Wei-Fen Xie, +1 more
TL;DR: In this article , the authors evaluated the 1-year outcomes in patients with severe COVID-19, who were recruited in their previous UC-MSC clinical trial, and the results showed that the long-term consequences of human umbilical cord-derived mesenchymal stem cell treatment for COVID19 patients are yet to be reported.
Journal ArticleDOI

Hepatitis B virus (HBV) antigen-pulsed monocyte-derived dendritic cells from HBV-associated hepatocellular carcinoma patients significantly enhance specific T cell responses in vitro.

M. Shi, +7 more
- 21 Dec 2006 - 
TL;DR: HBV antigen‐pulsed MoDC from HCC patients with chronic hepatitis B could induce HBV‐specific T cell response in vitro, indicating that antigen pulse could substantially reverse the impaired function of MoDC in primary H CC patients with active chronic hepatitisB.
Journal ArticleDOI

Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: Too alarming?

Qing-Lei Zeng, +9 more
- 01 Nov 2016 - 
Journal ArticleDOI

Persistent Viral Presence Determines the Clinical Course of the Disease in COVID-19.

De Chang, +16 more
- 01 Sep 2020 - 
TL;DR: Patients with persistent viral presence have more severe disease outcomes including extensive lung involvement and requirement of respiratory support and the data suggest that viral persistence is the key determining factor of the disease severity.